Back to GetFilings.com



Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
   


FORM 10-Q

     
(Mark One)    
x   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended September 27, 2003
or

     
o   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from        to        

Commission file number: 0-27892

SIPEX Corporation
(Exact Name of Registrant as Specified in its Charter)

     
Delaware
(State or Other Jurisdiction of
Incorporation or Organization)
  04-6135748
(I.R.S. Employer
Identification No.)
 
233 South Hillview Drive, Milpitas, California
(Address of principal executive offices)
  95035
(Zip Code)

(408) 934-7500
Registrant’s telephone number, including area code


Former name, former address and former fiscal year if changed since last report.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x          No o

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes x          No o

There were 28,257,100 shares of the Registrant’s Common Stock issued and outstanding as of November 7, 2003.



 


TABLE OF CONTENTS

Part I: FINANCIAL INFORMATION
Item 1: Financial Statements
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED STATEMENTS OF OPERATIONS
CONSOLIDATED STATEMENTS OF CASH FLOWS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Item 3. Quantitative and Qualitative Disclosures about Market Risk:
Item 4. Controls and Procedures
Part II: OTHER INFORMATION
Item 1. Legal Proceedings
Item 2. Changes in Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Submission of Matters to a Vote of Security Holders
Item 5. Other Information
Item 6. Exhibits and Reports on Form 8-K
SIGNATURES
EXHIBIT 31.1
EXHIBIT 31.2
EXHIBIT 32.1
EXHIBIT 32.2


Table of Contents

FORM 10-Q
NINE MONTHS ENDED SEPTEMBER 27, 2003

INDEX

                 
Item            
Number           Page

         
PART I:   FINANCIAL INFORMATION        
Item 1.   Financial Statement        
    Consolidated Balance Sheets at September 27, 2003 and December 31, 2002     3  
    Consolidated Statements of Operations for the three and nine months ended September 27, 2003 and September 28, 2002     4  
    Consolidated Statements of Cash Flows for the nine months ended September 27, 2003 and September 28, 2002     5  
    Notes To Consolidated Financial Statements     6  
Item 2.   Management’s Discussion and Analysis of Financial Condition and Results of Operations     13  
Item 3.   Quantitative and Qualitative Disclosure about Market Risk     29  
Item 4.   Controls and Procedures     30  
PART II:   OTHER INFORMATION        
Item 1.   Legal Proceedings     31  
Item 2.   Changes in Securities and Use of Proceeds     31  
Item 3.   Defaults Upon Senior Securities     31  
Item 4.   Submission of Matters to a Vote of Security Holders     31  
Item 5.   Other Information     31  
Item 6.   Exhibits and Reports on Form 8-K     31  
    SIGNATURES     32  

2


Table of Contents

Part I: FINANCIAL INFORMATION

Item 1: Financial Statements

SIPEX CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
(Unaudited)

                     
        September 27, 2003   December 31, 2002
       
 
ASSETS
               
 
Current assets:
               
 
Cash and cash equivalents
  $ 10,206     $ 6,489  
 
Short-term investment securities
    6,486       9,980  
 
Accounts receivable, net
    8,058       7,278  
 
Accounts receivable, net, related party (note 3)
    3,069        
 
Inventories, net
    15,094       14,393  
 
Prepaid expenses and other current assets
    2,543       3,446  
 
   
     
 
   
Total current assets
    45,456       41,586  
Property, plant, and equipment, net
    51,766       56,997  
Other assets
    456       203  
 
   
     
 
   
Total assets
  $ 97,678     $ 98,786  
 
   
     
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
               
 
Current liabilities:
               
 
Accounts payable
  $ 6,365     $ 8,103  
 
Accrued expenses
    4,728       3,570  
 
Accrued restructuring costs
          755  
 
Deferred income, related party (note 3)
    4,006       1,383  
 
   
     
 
   
Total current liabilities
    15,099       13,811  
Long-term debt, related party (note 3)
    21,244       10,455  
 
   
     
 
   
Total liabilities
    36,343       24,266  
 
   
     
 
Commitments (Note 9)
           
Shareholders’ equity: Preferred stock, $0.01 par value, 1,000 shares authorized and no shares issued or outstanding
           
 
Common stock, $0.01 par value, 60,000 shares authorized; 28,216 and 28,031 shares issued and outstanding at September 27, 2003 and December 31, 2002, respectively
    282       280  
 
Additional paid-in capital
    177,450       175,489  
 
Accumulated deficit
    (116,384 )     (101,179 )
 
Accumulated other comprehensive loss
    (13 )     (70 )
 
   
     
 
   
Total shareholders’ equity
    61,335       74,520  
 
   
     
 
   
Total liabilities and shareholders’ equity
  $ 97,678     $ 98,786  
 
   
     
 

See accompanying notes to consolidated financial statements

3


Table of Contents

SIPEX CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)

                                         
            Three Months Ended   Nine Months Ended
           
 
            September 27,   September 28,   September 27,   September 28,
            2003   2002   2003   2002
           
 
 
 
Net sales
  $ 10,462     $ 16,625     $ 31,273     $ 49,677  
Net sales, related party (note 3)
    5,950             15,146        
 
   
     
     
     
 
       
Net sales, before fair value of debt conversion rights
    16,412       16,625       46,419       49,677  
 
Fair value of debt conversion rights, related party (note 3)
    (1,214 )           (1,214 )      
 
   
     
     
     
 
     
Total net sales
    15,198       16,625       45,205       49,677  
 
 
Cost of sales
    7,881       21,272       27,215       54,092  
Cost of sales, related party (note 3)
    3,748             12,246        
Restructuring costs
          1,909       (37 )     1,909  
 
   
     
     
     
 
   
Total cost of sales
    11,629       23,181       39,424       56,001  
 
   
     
     
     
 
 
Gross profit (loss)
    3,569       (6,556 )     5,781       (6,324 )
 
Operating expenses:
                               
 
Research and development
    3,377       3,407       9,738       9,680  
 
Marketing and selling
    1,759       1,813       5,126       6,286  
 
General and administrative
    1,563       1,816       5,679       6,116  
 
Reorganization
          1,623             1,623  
 
Restructuring and facility exit costs
    (29 )     3,806       (329 )     3,806  
 
Impairment charges
          1,819             1,819  
 
Impairment of goodwill
                      2,984  
 
   
     
     
     
 
       
Total operating expenses
    6,670       14,284       20,214       32,314  
 
Loss from operations
    (3,101 )     (20,840 )     (14,433 )     (38,638 )
 
Interest income
    31       45       96       120  
Interest expense
    (216 )           (556 )     (81 )
Other expense, net
    (32 )     (102 )     (21 )     (813 )
 
   
     
     
     
 
       
Total other expense, net
    (217 )     (57 )     (481 )     (774 )
 
Loss before income taxes
    (3,318 )     (20,897 )     (14,914 )     (39,412 )
 
Income tax expense
    27       178       291       32,113  
 
   
     
     
     
 
Net loss
  $ (3,345 )   $ (21,075 )   $ (15,205 )   $ (71,525 )
 
   
     
     
     
 
Net loss per common share — basic and diluted
  $ (0.12 )   $ (0.75 )   $ (0.54 )   $ (2.66 )
 
   
     
     
     
 
Weighted average common shares outstanding — basic and diluted
    28,145       27,955       28,077       26,920  
 
   
     
     
     
 

See accompanying notes to consolidated financial statements

4


Table of Contents

SIPEX CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

                         
            Nine Months Ended
           
            September 27,   September 28,
            2003   2002
           
 
Operating activities:
               
 
Net loss
  $ (15,205 )   $ (71,525 )
 
Adjustments to reconcile net loss to net cash used in operating activities:
               
   
Fair value of debt conversion rights (note 3)
    1,214        
   
Deferred income taxes
          31,851  
   
Provision (reversal) for uncollectible receivables and returns and allowances
    (604 )     1,890  
   
Fixed asset impairment loss
    649        
   
Stock compensation expense
    56        
   
(Gain) loss on fixed asset disposition
    196       (123 )
   
Depreciation and amortization
    5,799       9,160  
   
Impairment charges
          1,819  
   
Restructuring and reorganization charges
          7,338  
   
Amortization of discount on long-term debt, related party (note 3)
    242        
   
Changes in current assets and liabilities:
               
     
Accounts receivable
    (3,245 )     (837 )
     
Inventories, net
    (701 )     3,732  
     
Prepaid expenses and other current assets
    903       (142 )
     
Other assets
    (138 )      
     
Accounts payable
    (1,738 )     4,961  
     
Accrued expenses
    1,158       1,180  
     
Accrued restructuring costs
    (755 )      
     
Deferred income, related party (note 3)
    2,623       100  
 
   
     
 
       
Net cash used in operating activities
    (9,546 )     (10,596 )
 
   
     
 
Investing activities:
               
 
Purchase of short-term investment securities
    (7,469 )      
 
Proceeds from maturity of short-term investment securities
    10,963       (5,994 )
 
Purchase of property, plant and equipment
    (1,413 )     (3,569 )
 
   
     
 
       
Net cash provided by (used in) investing activities
    2,081       (9,563 )
 
   
     
 
Financing activities:
               
 
Debt issuance costs
    (128 )      
 
Proceeds from issuance of common stock
    694       24,226  
 
Proceeds from issuance of convertible secured notes, related party (note 3)
    10,560       12,000  
 
Payments of debt obligations
          (7,396 )
 
   
     
 
       
Net cash provided by financing activities
    11,125       28,830  
Effect of foreign currency exchange rate changes on cash and cash equivalents
    57       (61 )
 
   
     
 
Increase in cash and cash equivalents
    3,717       8,610  
Cash and cash equivalents, beginning of period
    6,489       4,874  
 
   
     
 
Cash and cash equivalents, end of period
  $ 10,206     $ 13,484  
 
   
     
 
Supplemental cash flow information:
               
 
Cash paid during the period for:
               
   
Income taxes
  $ 143     $ 81  
   
Interest
  $     $ 12  

See accompanying notes to consolidated financial statements

5


Table of Contents

SIPEX CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

Note 1. Basis of Presentation

Unaudited Interim Financial Information

     We have prepared the accompanying consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. As used herein, “Sipex,” the “Company,” “we,” “our” and similar terms include Sipex Corporation and its wholly-owned subsidiaries, unless the context indicates otherwise. These consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of the consolidated balance sheets, operating results and cash flows for the periods presented. Operating results for the three and nine months ended September 27, 2003 are not necessarily indicative of the results that may be expected for the year ending December 31, 2003 due to cyclical and other factors. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2002. Certain prior period amounts have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss as previously reported.

Principles of Consolidation

     The consolidated financial statements include the accounts of Sipex and all of its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Stock-Based Compensation

     In December 2002, the FASB issued SFAS No. 148, “Accounting for Stock-Based Compensation — Transition and Disclosure — an Amendment of SFAS 123.” SFAS No. 148 provides additional transition guidance for those entities that elect to voluntarily adopt the provisions of SFAS No. 123, “Accounting for Stock-Based Compensation.” Furthermore, SFAS No. 148 mandates prominent disclosures in both interim and year-end financial statements about the fair value based method of accounting for stock-based employee compensation and the effect of the method used on reported results. SFAS No. 148 is effective for fiscal years ending after December 15, 2002. The adoption of SFAS No. 148 did not have a material effect on the Company’s financial position or results of operations as the Company does not intend to adopt the fair value method of accounting for stock-based employee compensation.

     The Company accounts for its stock-based employee compensation plans under the recognition and measurement principles of APB Opinion No. 25, “Accounting for Stock Issued to Employees,” and related interpretations. The Company recorded $5,600 and $50,000 in stock based compensation, reflected in net loss for the three and nine months ended September 27, 2003, respectively. The Company principally grants employee stock options at exercise prices equal to the market value of the underlying common stock on the date of grant. The following table illustrates the effect on net loss and net loss per share as if the Company had applied the fair value recognition provisions of FASB Statement No. 123, “Accounting for Stock Based Compensation,” as amended by SFAS No. 148, to stock-based employee compensation in each period: (in thousands, except per share data)

                                   
      3 Months Ended   9 Months Ended
     
 
      September 27,   September 28,   September 27,   September 28,
      2003   2002   2003   2002
     
 
 
 
Net loss
  $ 3,345     $ 21,075     $ 15,205     $ 71,525  
Less: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects
    4,593       4,109       13,170       11,226  
 
   
     
     
     
 
Pro forma net loss
    7,938       25,184       28,375       82,751  
 
   
     
     
     
 

6


Table of Contents

                                   
      3 Months Ended   9 Months Ended
     
 
      September 27,   September 28,   September 27,   September 28,
      2003   2002   2003   2002
     
 
 
 
Net loss per share: